- Nous has secured €2.315 million in seed funding to accelerate the commercialisation of Koncentra, its branded botanical functional ingredient for the energy category.
- The funding round was led by dsm-firmenich Ventures, with participation from FoodSeed, the foodtech programme of CDP Venture Capital's National Accelerator Network.
- Koncentra is produced using Nous’ proprietary extraction technology and is designed to support energy, focus, and mood.
- The new funding will enable Nous to commission additional clinical studies and strengthen the scientific evidence supporting Koncentra.
- Lorenzo Pessini, CEO of Nous, described the investment as a significant milestone in the company's transition from scientific validation to broader commercialisation.
- Nous develops science-backed botanical ingredients with a focus on natural alternatives for the energy category.
- Nous plans to expand distribution of Koncentra into the US market from November 2026.
- By the end of 2027, Nous aims to publish at least three clinical studies and reach an annual production capacity of at least 60 tonnes of Koncentra.
Nous, an Italian ingredient company, has raised €2.315 million in seed funding to accelerate the commercialization of Koncentra, its botanical functional ingredient targeting the energy sector. The funding round was led by dsm-firmenich Ventures with participation from FoodSeed, part of CDP Venture Capital's National Accelerator Network.1234678
Nous develops science-backed botanical ingredients using proprietary extraction technology, focusing on natural alternatives for energy. Koncentra is designed to support energy, focus, and mood, and is currently undergoing clinical research and forming commercial partnerships to expand into international markets.
CEO Lorenzo Pessini described the investment as a significant milestone, stating, “Support from investors with deep expertise in ingredients, foodtech and market scale-up gives us the resources to strengthen the scientific position of Koncentra, expand our supply chain, and build the next generation of functional ingredients.”5
The funding will enable Nous to commission additional clinical studies, enhance scientific evidence for Koncentra, and expand its supply chain across Europe and Asia. The company plans to enter the US market by November 2026 and aims to publish at least three clinical studies by the end of 2027, with a production capacity target of 60 tonnes of Koncentra annually.
As demand for natural ingredients grows, Nous is expanding its network of commercial partners across Europe, with a focus on the food, beverage, and nutraceutical sectors.
“The round was led by dsm-firmenich Ventures, with participation from FoodSeed, the foodtech program of CDP Venture Capital. Nous plans to expand Koncentra's distribution into the US market from November 2026 and aims to reach an annual production capacity of 60 tonnes by end of 2027.”
Tech.eu
